Paradigm Biocapital Advisors LP
Q3 2023 13F-HR Holdings
Net value change ($000)
+179,482
(13.9%)
New positions
6
Sold out positions
6
Turnover %
21.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ARGX | 73,090 | 131.8% |
| OLMA | 62,683 | 186.1% |
| IRON | 59,772 | NEW |
| CRNX | 39,658 | 157.8% |
| ACLX | 31,746 | 42.8% |
| TGTX | 30,255 | NEW |
| NUVL | 28,056 | 59.4% |
| BCYC | 22,506 | 44.4% |
| Mirati Therapeutics, Inc. | 20,500 | 39.3% |
| UTHR | 16,789 | 31.9% |
Top Reduces (Value $000, Stocks/ETFs)
| Karuna Therapeutics, Inc. | -61,500 | -100.0% |
| ONC | -38,529 | -100.0% |
| INCY | -33,297 | -38.7% |
| VIR | -24,879 | -100.0% |
| MDGL | -19,635 | -100.0% |
| MLTX | -18,850 | -100.0% |
| Theseus Pharmaceuticals, Inc. | -18,197 | -100.0% |
| SNDX | -16,033 | -31.6% |
| VOR | -6,268 | -31.4% |
| IMCR | -4,292 | -5.6% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
7,491
(0.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|